CrossAssetDataThe Company File
···
TLRY

Tilray Brands, Inc.

Tilray Brands, Inc. is classed by the SEC under Medicinal Chemicals & Botanical Products (industry code 2833), based in New York, NY. In its latest annual figures on file, for the fiscal year ended 2025-05-31, it reported revenue of $821 million and a loss of $2.2 billion (its filed statements).

Product business Medicinal Chemicals & Botanical Products New York, NY filings since 2018 8 of 9 filed, 1 estimated
Ask the desk about TLRY → Compare TLRY with TRLV → Price chart on TradingView ↗ Full EDGAR file ↗ Watch TLRY →

Sector peers: TRLVCRONUSNADFTX

5.3/10headline grade
vs its business-model standard
4.9/10past 5.9/10present 4.7/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2833, Medicinal Chemicals & Botanical Products); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.3 out of ten, 8 of 9 metrics filed and 1 estimated: past 4.9 out of ten, present 5.9 out of ten, future 4.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 1.3 out of ten. 5 warning events since 2018; the latest 2025-03-25. 13th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.4 out of ten. +26.2% a year over 8 filed years; profitable in 0 of 10. 54th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 9.2 out of ten. CrossAssetData estimate 9.2/10, confidence 35 of 100 (one part). 92nd percentile among 18 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 4.8 out of ten. ROE -8%: lost 8¢ per shareholder dollar. Leverage 31%: owes 31¢ per asset dollar. 47th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 6.6 out of ten. top 34% of 18 in its family; net margin -13.3%. 66th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 7.3 out of ten. top 27% of 12 in its family for leadership; chief executive since 2021. 73rd percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 3.2 out of ten. bottom 32% of 18 in its family for room to expand. 32nd percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.4 out of ten. top 46% of 18 in its family for growth drivers. 54th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 6.8 out of ten. top 32% of 18 in its family for expectations against reality. 68th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-07-28 for the period ended 2026-05-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-10-08 for the period ended 2026-08-31 (on EDGAR). Newest results release: Form 8-K filed 2026-10-08 (on EDGAR). Newest filing: Form 10-Q, 2026-10-08. Filings on record since 2018. Read from EDGAR 2026-10-12.

Where the revenue comes from

Lines of business in fiscal 2026: Distribution Business 36%, Cannabis 29%, Beverage Alcohol Business 28%, Wellness Business 7%. By geography: EMEA 49%, United States 27%, Canada 24%, Rest of World 1%. As tagged in its annual report (Form 10-K, filed 2026-07-28).

Who runs it

Simon, Irwin D (President and CEO); Merton, Carl A (Chief Financial Officer); Faltischek, Denise M (Chief Strategy Officer); Gendel, Mitchell (Global General Counsel); Clanachan, David F (director); Cohen, Steven Michael (director); Herhalt, Johann Michael (director); Hopkinson, David G. (director); Looney, Thomas P. (director); Persofsky, Renah (director). 10 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.